ONCO logo

Oncopeptides Stock Price

Symbol: OM:ONCOMarket Cap: SEK 1.1bCategory: Pharmaceuticals & Biotech

ONCO Share Price Performance

SEK 4.80
2.47 (106.01%)
75.6% overvalued intrinsic discount
SEK 2.73
Fair Value
SEK 4.80
2.47 (106.01%)
75.6% overvalued intrinsic discount
SEK 2.73
Fair Value
Price SEK 4.80
AnalystConsensusTarget SEK 2.73
DailyInvestors SEK 2.56

ONCO Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value SEK 2.73 75.6% overvalued intrinsic discount

Agreements In Europe And Japan Will Unlock Global Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
DA
DailyInvestors·Updated
Fair Value SEK 2.56 87.5% overvalued intrinsic discount

Oncolytics Biotech: A Beacon of Hope in Cancer Treatment

0users have liked this narrative
1users have commented on this narrative
4users have followed this narrative

ONCO Community Fair Values

Recent ONCO News & Updates

No updates

Oncopeptides AB (publ) Key Details

SEK 39.8m

Revenue

SEK 2.3m

Cost of Revenue

SEK 37.6m

Gross Profit

SEK 315.1m

Other Expenses

-SEK 277.6m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 21, 2025
Earnings per share (EPS)
-1.23
Gross Margin
94.25%
Net Profit Margin
-696.66%
Debt/Equity Ratio
-2,026.1%

Oncopeptides AB (publ) Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About ONCO

Founded
2000
Employees
75
CEO
Sofia Heigis
WebsiteView website
www.oncopeptides.com/sv

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Swedish Market Performance

  • 7 Days: -2.2%
  • 3 Months: 3.1%
  • 1 Year: 3.0%
  • Year to Date: -0.9%
Over the last 7 days, the market has dropped 2.2%, driven by a decline of 2.5% in the Industrials sector. Overall the market has been flat in the last year. Looking forward, earnings are forecast to grow by 17% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading